DIREVO announces transfer of patents from Evotec
DIREVO Biotech AG announced that it has entered into an agreement with Evotec under which Evotec will transfer certain patents to DIREVO that are currently licensed by DIREVO. Such patents protect key components of DIREVO's unique and proven protein/strain engineering platform. Using this platform, DIREVO develops products both independently and with global leaders such as AstraZeneca/MedImmune and Pfizer, as well as Danisco/Genencor and Nestlé.
"This is a very important milestone for the company, because DIREVO now owns essential parts of intellectual property protecting its technology" said Dr. Thomas von Rüden, CEO of DIREVO. "This will give us much greater flexibility in the company's future corporate development, e.g., it will allow us to spin out legal entities able to focus and further develop and customize the technology in their own markets"
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.